Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $75.00 Consensus PT from Analysts

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have been assigned a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are currently covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $75.00.

Several equities analysts have weighed in on the company. Scotiabank cut their price target on Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating for the company in a report on Friday, December 13th. BTIG Research downgraded shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, December 12th. Wells Fargo & Company upped their price target on shares of Keros Therapeutics from $88.00 to $111.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Wedbush reaffirmed an “outperform” rating and set a $84.00 target price on shares of Keros Therapeutics in a research report on Thursday, November 7th. Finally, Guggenheim downgraded shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, December 16th.

Keros Therapeutics Stock Down 2.7 %

Shares of KROS opened at $12.48 on Friday. Keros Therapeutics has a twelve month low of $12.22 and a twelve month high of $73.00. The firm has a 50 day moving average of $39.77 and a 200 day moving average of $47.88. The company has a market capitalization of $505.53 million, a P/E ratio of -2.40 and a beta of 1.43.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The business had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company’s revenue for the quarter was up 4750.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.33) EPS. On average, sell-side analysts expect that Keros Therapeutics will post -5.26 EPS for the current year.

Institutional Investors Weigh In On Keros Therapeutics

A number of large investors have recently modified their holdings of the company. KBC Group NV boosted its position in shares of Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after acquiring an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after purchasing an additional 280 shares during the last quarter. Values First Advisors Inc. acquired a new position in Keros Therapeutics in the third quarter valued at approximately $89,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Keros Therapeutics in the second quarter valued at approximately $128,000. Finally, LMR Partners LLP acquired a new stake in Keros Therapeutics during the third quarter worth approximately $213,000. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.